SCHEMBL5361045

SCHEMBL5361045

CCOP(=O)(OCC)C(N(C)c1ccccn1)P(=O)(OCC)OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
POLB P06746 1/20 0.43
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
GAA P10253 1/20 0.39
CHRM2 P08172 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
DRD1 P21728 1/20 0.36
SLC6A2 P23975 1/20 0.36
HTR2A P28223 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
OPRK1 P41145 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363358 0.81 ALDH1A1 (0.46) ALDH1A1LMNAMAPTPOLBCYP2C19
SCHEMBL5359433 0.80 POLB (0.37) ALDH1A1LMNAMAPTPOLBCYP2D6
SCHEMBL5359454 0.76 KDM4E (0.48) ALDH1A1MAPTPOLBCYP2D6CYP2C19
SCHEMBL5361049 0.76 LMNA (0.50) ALDH1A1LMNAMAPTPOLBCYP2D6
SCHEMBL5360999 0.70 FDPS (0.58) ALDH1A1POLBGAANPSR1SMN1; SMN2
SCHEMBL8166890 0.70 LMNA (0.44) ALDH1A1LMNAMAPTPOLBGAA
SCHEMBL7752752 0.70 CYP2D6 (0.52) ALDH1A1LMNAPOLBCYP2D6CYP2C19
SCHEMBL85721 0.69 CYP2D6 (0.55) ALDH1A1LMNACYP2D6CYP2C19CHRM2
SCHEMBL5007472 0.69 ALDH1A1 (0.49) ALDH1A1LMNAMAPTPOLBGAA
SCHEMBL14908562 0.69 TSHR (0.41) MAPTPOLBCYP2C19GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208481-B2 Aminodiphosphonate apolipoprotein E modulators ILEX PRODUCTS, INC. (US) 2007-04-24 US claimed
US-20050075317-A1 Aminodiphosphonate apolipoprotein e modulators PHAN HIEU TRUNG (CH) 2005-04-07 US claimed
EP-1482897-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS Ilex Products, Inc. (US) 2004-12-08 EP claimed
WO-2003070169-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS ILEX PRODUCTS, INC. (US) 2003-08-28 WO claimed
US-7208481-B2 Aminodiphosphonate apolipoprotein E modulators ILEX PRODUCTS, INC. (US) 2007-04-24 US disclosed
US-20050075317-A1 Aminodiphosphonate apolipoprotein e modulators PHAN HIEU TRUNG (CH) 2005-04-07 US disclosed
EP-1482897-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS Ilex Products, Inc. (US) 2004-12-08 EP disclosed
WO-2003070169-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS ILEX PRODUCTS, INC. (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075317-A1 Aminodiphosphonate apolipoprotein e modulators APOB, APOL1, NAPEPLD ALDH1A1 3096/4885LMNA 2383/4885MAPT 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.